Ottimo Pharma is a private biotech company focused on developing bifunctional medicines aimed at extending the lives of individuals with cancer. The company is advancing its lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody designed for multiple solid tumor indications. Ottimo Pharma is also working on a pipeline of follow-on bifunctional assets to further its mission in oncology therapeutics.
Leadership & Board
Current Number of Employees20
Current LinkedIn Followers5,964
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$140M
Total Amount Raised$140M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$140M
Latest Funding Amount$140M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Ottimo Pharma had 20 employees as of September 7, 2026. The number of employees increased by 0 (0.00%) week-over-week.
20Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Ottimo Pharma had 5,964 followers as of September 7, 2026. The number of followers increased by 2 (0.03%) week-over-week.
5,964Latest Followers Count
2(0.03%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.